3-[5-chloro-3-fluoro-6-[(3R)-3-(2-methylpropyl)piperazin-1-yl]pyridin-2-yl]-2H-pyrazolo[3,4-b]pyridine | 1319591-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[5-chloro-3-fluoro-6-[(3R)-3-(2-methylpropyl)piperazin-1-yl]pyridin-2-yl]-2H-pyrazolo[3,4-b]pyridine
• CAS: 1319591-04-2
• 化学式: C₁₉H₂₂ClFN₆
• 分子量: 388.875
• InChiKey: PIMCSYMHXDJBLQ-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PYRAZOLOPYRIDINE KINASE INHIBITORS
  申请人：Jimenez Juan-Miguel

  公开号：US20130053395A1

  公开（公告）日：2013-02-28

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及用作蛋白激酶抑制剂的化合物。本发明还提供了包含该化合物的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病、病况或疾患的方法。本发明还提供了制备本发明化合物的方法。
• Stem cell modulation II
  申请人：University of Canberra

  公开号：US10736892B2

  公开（公告）日：2020-08-11

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.

  本发明公开了调节癌症干细胞的方法和组合物。更具体地说，本发明公开了蛋白激酶C theta抑制剂（PKC-θ）的用途，用于抑制包括癌症干细胞在内的PKC-θ过表达细胞的生长，增强化疗药物或照射对癌细胞的生物效应，治疗癌症，包括转移性癌症和/或预防癌症复发。
• STEM CELL MODULATION II
  申请人：EpiAxis Therapeutics Pty Ltd

  公开号：EP3046560B1

  公开（公告）日：2021-01-06
• Stem Cell Modulation II
  申请人：UNIVERSITY OF CANBERRA

  公开号：US20160354367A1

  公开（公告）日：2016-12-08

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
• Compositions for Modulating Cancer Stem Cells and Uses Therefor
  申请人：University of Canberra

  公开号：US20170266140A1

  公开（公告）日：2017-09-21

  Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.